You are here

vaccines

Russia claims 92% efficacy for Sputnik COVID-19 shot

Russia claims 92% efficacy for Sputnik COVID-19 shot

Pharmaforum

Flag link:

Medigen, BlueWillow collaborate to develop SARS-CoV-2 intranasal vaccine

Medigen, BlueWillow collaborate to develop SARS-CoV-2 intranasal vaccine

Pharmaceutical Business Review

BlueWillow Biologics

intranasal vaccines

Flag link:

No Surprise Here: BioNTech's Q3 Results Driven by Its COVID-19 Vaccine Program

No Surprise Here: BioNTech's Q3 Results Driven by Its COVID-19 Vaccine Program

Motley Fool

Flag link:

Novel vaccines typically take 8 years of clinical development: Study

Novel vaccines typically take 8 years of clinical development: Study

RAPS.org

clinical trials

drug development

Flag link:

The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race

The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race

Stat

drug development

Flag link:

HHS Secretary Alex Azar Predicts There Will Be Enough Covid-19 Vaccine Doses For All Americans By Spring

HHS Secretary Alex Azar Predicts There Will Be Enough Covid-19 Vaccine Doses For All Americans By Spring

Forbes

Flag link:

Game on: Pfizer, BioNTech prepare to put COVID-19 shot distribution plan to the test after interim readout

Game on: Pfizer, BioNTech prepare to put COVID-19 shot distribution plan to the test after interim readout

Fierce Pharma

drug manufacturing

Flag link:

CureVac climbs on vaccine data despite tolerability questions

CureVac climbs on vaccine data despite tolerability questions

Fierce Biotech

clinical trials

Flag link:

Novavax Didn't Come Close to Analysts' Q3 Estimates -- and It's No Big Deal

Novavax Didn't Come Close to Analysts' Q3 Estimates -- and It's No Big Deal

Motley Fool

Flag link:

Novavax to Start Phase III COVID-19 Trials in U.S. with Fast Track Designation

Novavax to Start Phase III COVID-19 Trials in U.S. with Fast Track Designation

BioSpace

clinical trials

Flag link:

Three Billionaires Behind Pfizer's Vaccine Partner BioNTech Are $2 Billion Richer After It Announces Covid-19 Vaccine Results

Three Billionaires Behind Pfizer's Vaccine Partner BioNTech Are $2 Billion Richer After It Announces Covid-19 Vaccine Results

Forbes

Flag link:

After Pfizer's vaccine data, analysts say COVID19 drugmakers face questions about long-term sales prospects

After Pfizer's vaccine data, analysts say COVID19 drugmakers face questions about long-term sales prospects

Fierce Pharma

Gilead Sciences

clinical trials

Flag link:

Pfizer Soars as Vaccine Prevents 90% of Covid Cases in Study

Pfizer Soars as Vaccine Prevents 90% of Covid Cases in Study

Bloomberg

clinical trials

Flag link:

CVS CEO: Pharmacies Ready To Distribute Covid-19 Vaccines Once Approved

CVS CEO: Pharmacies Ready To Distribute Covid-19 Vaccines Once Approved

Forbes

Flag link:

3 Red Flags for Inovio Pharmaceuticals' Future

3 Red Flags for Inovio Pharmaceuticals' Future

Motley Fool

Inovio Pharmaceuticals

Flag link:

First COVID-19 Vaccine Doses To Go To Health Workers, Say CDC Advisers

First COVID-19 Vaccine Doses To Go To Health Workers, Say CDC Advisers

NPR

healthcare workers

Flag link:

AZ’s Q3 results disappoint – but COVID19 vaccine trial is still on track

AZ’s Q3 results disappoint – but COVID19 vaccine trial is still on track

Pharmaforum

Flag link:

Building a vaccine at light speed: mRNA COVID vaccine development

Building a vaccine at light speed: mRNA COVID vaccine development

RAPS.org

Flag link:

Trial chief tips AstraZeneca COVID-19 vaccine for 2020 data drop

Trial chief tips AstraZeneca COVID-19 vaccine for 2020 data drop

Fierce Biotech

clinical trials

Flag link:

3 Big Advantages Novavax Has Over Moderna

3 Big Advantages Novavax Has Over Moderna

Motley Fool

Moderna Therapeutics

Flag link:

Pages